BMS lowers 2017 guidance

Bristol-Myers Squibb Co. (NYSE:BMY) fell $2.73 to $46.82 on Thursday after releasing 2016 earnings and lowering its non-GAAP EPS guidance for 2017. The company now

Read the full 259 word article

User Sign In